首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Defining the risks of mesenchymal stromal cell therapy
Authors:Darwin J Prockop  Malcolm Brenner  Willem E Fibbe  Edwin Horwitz  Katarina Le Blanc  Donald G Phinney  Paul J Simmons  Luc Sensebe  Armand Keating
Institution:1. Texas A&M Health Science College of Medicine, Institute for Regenerative Medicine at Scott & White, Temple, Texas, USA;2. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA;3. Leiden University Medical Center, Leiden, the Netherlands;4. Children''s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA;5. Karolinska Institutet, Stockholm, Sweden;6. Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA;7. Center for Stem Cell Research, University of Texas Health Sciences Center, Houston, Texas, USA;8. Médical et Scientifique EFS Centre-Atlantique, Tours, France;9. Princess Margaret Hospital, Toronto, Ontario, Canada;3. Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, South Carolina 29425;4. Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425;5. Interdisciplinary Science and Technology Research Academy (ISTRA), Abeda Inamdar College, University of Pune, Azam Campus, Hidayatulah Road, Camp Pune 411001, India;6. Department of Biomedical Engineering/ND20, Cleveland Clinic, Cleveland, Ohio 44195;1. Division of Obstetrics and Gynecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden;2. Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden;3. Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden;4. Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA;2. Department of Pharmacology and Psychiatry, Mayo Clinic, Jacksonville, Florida, USA;3. Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA;1. Pediatric Blood and Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina;2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York;3. Hematology-Oncology Division, Charles Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada;4. Pediatric Oncology, Blood and Marrow Transplantation, Alberta Children''s Hospital, Calgary, Alberta, Canada;5. Pediatric Blood and Marrow Transplant Program, Texas Transplant Institute, Methodist Children''s Hospital of South Texas, San Antonio, Texas;6. Blood and Marrow Transplant Program, Benioff Children''s Hospital, University of California, San Francisco, California;7. Bone Marrow Transplant Program, Children''s Hospital, Louisiana State University Health Science Center, New Orleans, Louisiana;8. Department of Pediatric Hematology Oncology, Children''s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin;9. Pediatric BMT Program, Oregon Health & Science University, Portland, Oregon;10. Osiris Therapeutics, Columbia, Maryland;11. Division of Pediatric Hematology, Oncology, Stem Cell Transplantation, Ann & Robert H. Lurie Children''s Hospital of Chicago, Chicago, Illinois;1. Division of Cardiovascular Health and Disease, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA;2. Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA;3. Biomedical Engineering Program, College of Engineering and Applied Sciences, University of Cincinnati, Cincinnati, OH, USA;1. Department of Neurosurgery and Oncology, Neuro-Oncology Surgical Outcomes Research Laboratory, Johns Hopkins School of Medicine, Baltimore, Maryland, USA;2. Department of Neurosurgery, the National Institute of Neurology and Neurosurgery, Mexico City, Mexico
Abstract:We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号